|
Friday, December 8, 2023, 11:30 AM – 1:30 PM PT (2:30 PM – 4:30 PM ET)
Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Diffuse Large B-Cell Lymphoma (Part 2 of a 4-Part Series)A CME Friday Satellite Symposium and Virtual Event Preceding the 65th ASH Annual Meeting
Location
Omni San Diego Hotel 675 L Street San Diego, CA 92101 Phone: (619) 231-6664 Program Schedule — Pacific Time 11:00 AM – 11:30 AM — Registration and Lunch 11:30 AM – 1:30 PM — Educational Meeting Meeting Room Grand Ballroom (Level 2) This event will also be webcast live. Please see Registration tab for details. Faculty
Michael Dickinson, MD Hematologist Lead of Aggressive Lymphoma CAR-T Specialist Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne, Australia Grzegorz S Nowakowski, MD Professor of Medicine and Oncology Chair, Lymphoid Malignancy Group Enterprise Deputy Director, Clinical Research Mayo Clinic Comprehensive Cancer Center Vice-Chair, Division of Hematology Mayo Clinic Rochester, Minnesotaa Gilles Salles, MD, PhD Service Chief, Lymphoma Service Memorial Sloan Kettering Cancer Center New York, New York Laurie H Sehn, MD, MPH Chair, Lymphoma Tumour Group BC Cancer Centre for Lymphoid Cancer Clinical Professor of Medicine Division of Medical Oncology University of British Columbia Associate Editor, Blood Vancouver, British Columbia, Canada Jason Westin, MD, MS Director, Lymphoma Clinical Research Section Chief, Aggressive Lymphoma Professor Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston, Texas Moderator Neil Love, MD Research To Practice Miami, Florida This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, and Regeneron Pharmaceuticals Inc.
Program Schedule — Pacific Time
11:00 AM – 11:30 AM — Registration and Lunch 11:30 AM – 1:30 PM — Educational Meeting A detailed agenda will be available in the coming weeks. MODULE 1: Up-Front Management of Diffuse Large B-Cell Lymphoma (DLBCL) MODULE 2: Promising Investigational Approaches to First-Line Therapy for DLBCL MODULE 3: Selection and Sequencing of Novel Therapies for Relapsed/Refractory Disease MODULE 4: Incorporation of Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of DLBCL MODULE 5: Future Role of Bispecific Antibodies in DLBCL Target Audience
CME Credit Form Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY— Faculty panel disclosures to be provided. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, and Regeneron Pharmaceuticals Inc. Omni San Diego Hotel
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of diffuse large B-cell lymphoma.
There is no fee to participate in this hybrid event. For the in-person symposium in San Diego preregistration is required as seating is limited. NOTICE: Registration for this event is independent of registration for the ASH Annual Meeting. IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer. IN PERSON Registrationfor clinicians» IN-PERSON Registration for other/industry professionals*
Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis IN PERSON Registrationfor non-clinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. |